Bazedoxifene, a selective estrogen receptor modulator: Effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

Menopause

Volumn 16, Issue 6, 2009, Pages 1109-1115

  Archer, David F ^a   Pinkerton, Joann V ^b   Utian, Wulf H ^c   Menegoci, José C ^d   De Villiers, Tobie J ^e   Kin Yuen, Chui ^f   Levine, Amy B ^g   Chines, Arkadi A ^g   Constantine, Ginger D ^g  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Rapid Medical Research   (United States)

^d PONTIFÍCIA UNIVERSIDADE CATÓLICA DE SÃO PAULO   (Brazil)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f UNIVERSITY OF MANITOBA   (Canada)

^g PFIZER INC   (United States)

Author keywords

Bazedoxifene; Breast; Endometrial hyperplasia ovarian; Raloxifene; Selective estrogen receptor modulator

Indexed keywords

BAZEDOXIFENE; CALCIUM; PLACEBO; RALOXIFENE; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; BREAST; BREAST CARCINOMA; BREAST CYST; BREAST DISEASE; BREAST TUMOR; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ENDOMETRIUM TUMOR; FEMALE; FEMUR NECK; FIBROCYSTIC BREAST DISEASE; GYNECOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; OVARIAN ADENOFIBROMA; OVARY; OVARY CANCER; OVARY CYST; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THICKNESS; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; UTERUS BLEEDING; VAGINA BLEEDING; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BIOPSY; BREAST; BREAST CYST; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; INDOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OVARY; PLACEBOS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 70350443878     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a818db     Document Type: Article

References (34)

1. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health. Organization Task-Force for Osteoporosis. Osteoporos Int 1999;10:259-264. (Pubitemid 29476187)
2. Zizic TM, Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 2004;70:1293-1300.
3. O'Neill S, MacLennan. A, Bass S, et al. Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 2004;33: 910-919.
4. Baber RJ, O'Hara JL, Boyle FM. Hormone replacement therapy: to use or not to use? Med J Aust 2003;178:630-633. (Pubitemid 36763778)
5. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection, criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-326.
6. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001;86:755-760. (Pubitemid 32207492)
7. Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald. B. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999;18: 503-512. (Pubitemid 29291577)
8. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187: 521-527.
9. Ravn P, Nielsen TF, Christiansen C. What can be learned from the levormeloxifene experience? Acta Obstet Gynecol Scand 2006;85:135-142. (Pubitemid 43879232)
10. Novo Nordisk drops levormeloxifene. SCRIP 1998;2374:18.
11. Smith Kline Beecham drops idoxifene for osteoporosis. SCRIP 1999; 2431:21.
12. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen, receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008. (Pubitemid 41175771)
13. Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44:1654-1657.
14. Ronkin S, Clarke L. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. J Bone Miner Res 2001;16:S413. Abstract SU437.
15. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404. (Pubitemid 40734275)
16. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535.
17. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and activecontrolled clinical trial. J Bone Miner Res 2008;23:1923-1934.
18. Marin F, Barbancho MC. Clinical pharmacology of selective estrogen receptor modulators (SERMs). In: Sanchez AC, Alsina JCi, DueñasDiez JL, eds. Selective Estrogen Receptor Modulators. A New Brand of Multitarget Drugs. New York: Springer, 2006:49-65.
19. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256-266. (Pubitemid 39024525)
20. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537. (Pubitemid 24111008)
21. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741. (Pubitemid 43920726)
22. DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based casecontrol study. J Clin Oncol 2008;26:4151-4159.
23. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 2005;8:214-220. (Pubitemid 41224434)
24. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163-181. (Pubitemid 351612435)
25. Wanning L, Christoffersen. C, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Adverse effects of a SERM (Levormeloxifene): safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003;44:189-199. (Pubitemid 36315815)
26. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res. 2008;23(supp 1):S81.
27. Pfizer Inc. FABLYN® (lasofoxifene tartrate) 0.5 mg tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document, 08 September 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/ 2008-4381b1-02-Pfizer.pdf. Accessed October 27, 2008.
28. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-2197. (Pubitemid 29275701)
29. Boss SM, Huster WJ, Neild JA, Giant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women, Am J Obstet Gynecol 1997;177:1458-1464. (Pubitemid 28040243)
30. Fugere P, Scheele WH, Shah A, Strack TR, Giant MD, Jolly E. Uterine effects of raloxifene in comparison, with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-574. (Pubitemid 30207313)
31. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000; 95:95-103.
32. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation, Obstet Gynecol 2004;104:837-844. (Pubitemid 40458815)
33. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-1388. (Pubitemid 28439961)
34. Ettinger B, Black. DM, Mitlak BH, et al. Reduction of vertebral fracture risk, in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645. (Pubitemid 29384151)